S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
OTCMKTS:GNNSF

Genscript Biotech (GNNSF) Stock Price, News & Analysis

C$2.00
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
C$2.00
C$2.00
50-Day Range
C$1.75
C$2.44
52-Week Range
C$1.70
C$3.20
Volume
N/A
Average Volume
5,783 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GNNSF stock logo

About Genscript Biotech Stock (OTCMKTS:GNNSF)

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company also offers neoantigen peptides and peptide active pharmaceutical ingredients. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

GNNSF Stock Price History

GNNSF Stock News Headlines

Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Jefferies Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)
Genscript Biotech Corporation - Class H (GNNSF)
GenScript Named a BioSpace 2024 Best Place to Work
See More Headlines
Receive GNNSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genscript Biotech and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:GNNSF
CIK
N/A
Fax
N/A
Employees
6,937
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Jiange Meng (Age 56)
    Executive Chairman
    Comp: $693k
  • Ms. Weihui Shao (Age 44)
    CEO & COO
  • Ms. Ye Wang M.S. (Age 56)
    Co-Founder, President & Executive Director
    Comp: $461k
  • Mr. Shiniu Wei (Age 45)
    Chief Financial Officer
  • Dr. Fangliang Zhang EMBA (Age 59)
    Ph.D., Executive Director
    Comp: $271k
  • Dr. Li Zhu Ph.D. (Age 74)
    Chief Strategy Officer & Executive Director
    Comp: $280k
  • Dr. Brian Hosung Min Ph.D.
    CEO of Biologics Business
  • Ms. Wai Ling Wong A.C.I.S. (Age 44)
    A.C.S., Company Secretary

GNNSF Stock Analysis - Frequently Asked Questions

How have GNNSF shares performed in 2024?

Genscript Biotech's stock was trading at C$2.44 at the start of the year. Since then, GNNSF shares have decreased by 18.0% and is now trading at C$2.00.
View the best growth stocks for 2024 here
.

Are investors shorting Genscript Biotech?

Genscript Biotech saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 1,530,000 shares, a decline of 26.3% from the February 29th total of 2,076,000 shares. Based on an average daily trading volume, of 600 shares, the short-interest ratio is currently 2,550.0 days.
View Genscript Biotech's Short Interest
.

How do I buy shares of Genscript Biotech?

Shares of GNNSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNNSF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners